The push to reduce spending on foundational research is shortsighted, Tesla A. Monson and Marianne F. Brasil write.

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. Learn more about GPCR stock here.

AI-driven 'vibe coding' speeds up prototypes and widens hackathon entry, but risks producing students with shallow coding skills. Here's what employees really want, and how colleges, platforms and ...

As energy demand intensifies across data centers, industrial clusters, and electrification efforts, small modular reactors offer a scalable path forward. Yet, their success depends on preparing the ...

Ashok Elluswamy is an Elon Musk lieutenant, founding member of Tesla's Autopilot team, and the VP for AI software. How did he get there?

Dr. James McCaffrey presents a complete end-to-end demonstration of linear regression with two-way interactions between predictor variables. Standard linear regression predicts a single numeric value ...

In our latest installment of the Project 2025 series, we look at some of the social safety net policy changes sought by Project 2025 and proposed or accomplished by Trump.

With the welcome offer on The Platinum Card from American Express, you can earn as high as 175,000 points after spending $8,000 on eligible purchases within the first six months of card membership.

Do human rights still matter in a divided and dangerous world? Does the fact that they are violated invalidate them as tools for making the world safer and fairer? Are there concrete ways to ...

We're entering an exciting new era of deep ocean mapping', Celine Gerson, Fugro's group director for the Americas and president of Fugro USA, said.

This article originally published at After decades of defiance, a California hippie commune is defeated. Conservationists predict that only around half of the babies will survive. "There are so many ...

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech risks. Learn why VKTX stock is a strong buy.